Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dharmacon is a prominent provider of molecular biology tools and services, specializing in gene modulation and functional genomics. Founded in 1995 and currently operating as a brand under Revvity, the company is renowned for its pioneering work in RNA interference (RNAi) and CRISPR-Cas9 technologies. Its product portfolio includes high-performance siRNA, shRNA, and CRISPR reagents, as well as extensive libraries of cDNA and ORF clones. These tools enable researchers to precisely silence or edit genes to study biological pathways and identify potential therapeutic targets. Dharmacon's proprietary chemical modifications and bioinformatics-driven design algorithms ensure high specificity and potency in its genomic products. The company serves a global customer base across academia, biotechnology, and pharmaceutical industries.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Thermo Scientific Dharmacon.